VolitionRx (VNRX) Competitors $0.68 +0.02 (+2.70%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock VNRX vs. ANNX, FHTX, TLSA, CGC, ACB, VOR, SCPH, ZYBT, DSGN, and MREOShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Annexon (ANNX), Foghorn Therapeutics (FHTX), Tiziana Life Sciences (TLSA), Canopy Growth (CGC), Aurora Cannabis (ACB), Vor Biopharma (VOR), scPharmaceuticals (SCPH), Zhengye Biotechnology (ZYBT), Design Therapeutics (DSGN), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Its Competitors Annexon Foghorn Therapeutics Tiziana Life Sciences Canopy Growth Aurora Cannabis Vor Biopharma scPharmaceuticals Zhengye Biotechnology Design Therapeutics Mereo BioPharma Group VolitionRx (NYSE:VNRX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Which has higher earnings and valuation, VNRX or ANNX? VolitionRx has higher revenue and earnings than Annexon. VolitionRx is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.32M55.30-$35.32M-$0.25-2.71AnnexonN/AN/A-$138.20M-$1.29-1.67 Is VNRX or ANNX more profitable? Annexon has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Annexon N/A -70.04%-57.67% Do institutionals & insiders believe in VNRX or ANNX? 8.1% of VolitionRx shares are held by institutional investors. 10.4% of VolitionRx shares are held by company insiders. Comparatively, 11.9% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, VNRX or ANNX? VolitionRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Does the media refer more to VNRX or ANNX? In the previous week, VolitionRx had 4 more articles in the media than Annexon. MarketBeat recorded 15 mentions for VolitionRx and 11 mentions for Annexon. Annexon's average media sentiment score of 0.65 beat VolitionRx's score of -0.28 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VolitionRx 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer VNRX or ANNX? VolitionRx currently has a consensus price target of $3.50, indicating a potential upside of 416.22%. Annexon has a consensus price target of $12.50, indicating a potential upside of 480.05%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryVolitionRx and Annexon tied by winning 8 of the 16 factors compared between the two stocks. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$72.95M$18.64M$5.75B$20.90BDividend YieldN/AN/A4.53%3.60%P/E Ratio-1.88N/A30.4428.33Price / Sales55.3020.59391.6253.10Price / CashN/AN/A37.0323.77Price / Book-6.160.019.005.19Net Income-$35.32M-$15.34M$3.26B$992.10M7 Day Performance5.31%5.31%1.00%-0.20%1 Month Performance-12.52%-12.52%4.23%1.30%1 Year Performance-0.29%-0.29%28.45%10.56% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx2.1651 of 5 stars$0.68+2.7%$3.50+416.2%+4.7%$72.95M$1.32M-1.8880News CoverageAnalyst RevisionANNXAnnexon2.8989 of 5 stars$2.35-0.4%$12.50+431.9%-64.3%$258.93MN/A-1.9960Earnings ReportAnalyst UpgradeFHTXFoghorn Therapeutics2.313 of 5 stars$4.71+2.8%$12.00+154.8%-30.4%$258.91M$22.60M-3.96120TLSATiziana Life Sciences0.6769 of 5 stars$2.46+11.8%N/A+49.6%$257.07MN/A0.008Gap UpHigh Trading VolumeCGCCanopy Growth0.76 of 5 stars$1.58+26.4%N/A-81.0%$256.43M$225.65M-0.523,150Short Interest ↑High Trading VolumeACBAurora Cannabis0.6059 of 5 stars$5.21+16.3%N/A-25.6%$252.91M$246.72M-27.421,130High Trading VolumeVORVor Biopharma2.0017 of 5 stars$1.99-3.9%$5.63+182.8%+122.2%$252.01MN/A-1.21140Analyst RevisionSCPHscPharmaceuticals4.4197 of 5 stars$4.66+0.6%$14.00+200.4%-12.7%$246.77M$36.33M-2.5730Short Interest ↓ZYBTZhengye BiotechnologyN/A$5.38+3.3%N/AN/A$245.74M$25.53M0.00278Gap DownTrading HaltedDSGNDesign Therapeutics0.1628 of 5 stars$4.82+12.6%N/A-4.4%$243.74MN/A-4.3040News CoverageGap DownHigh Trading VolumeMREOMereo BioPharma Group2.2831 of 5 stars$1.52-0.7%$7.20+373.7%-63.3%$243.27M$10M-21.7140 Related Companies and Tools Related Companies ANNX Alternatives FHTX Alternatives TLSA Alternatives CGC Alternatives ACB Alternatives VOR Alternatives SCPH Alternatives ZYBT Alternatives DSGN Alternatives MREO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VNRX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access